Two companies blocked from comparing their generic products to Herceptin in IndiaBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g1632 (Published 19 February 2014) Cite this as: BMJ 2014;348:g1632
- Sanjeet Bagcchi
The drug company Roche has secured an injunction from the High Court of Delhi ordering two pharmaceutical companies—the Bangalore based Biocon and the US based Mylan—not to compare their generic versions of trastuzumab with Roche’s Herceptin.
However, an application from Roche for an interim order restraining the two companies “from launching, introducing, selling, marketing and/or distributing” their generic trastuzumab products in the Indian market, until appropriate tests and studies had been conducted, was rejected. The court ruled that an injunction was unnecessary because the companies were “not entitled to introduce or launch the drug without the requisite approvals” and such an injunction …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial